Valneva says European Commission to terminate purchase agreement for its VLA2001 COVID candidate

Valneva said on Monday it had received a notice of intent from the European Commission (EC) to terminate the advance purchase agreement for its VLA2001 COVID-19 candidate vaccine. 'The EC decision is regrettable especially as we continue to receive messages from Europeans who are looking for a more traditional vaccine solution,' CEO Thomas Lingelbach said. Valneva's vaccine relies on technology that has been used for decades, including in some shots against polio, influenza and hepatitis. Valneva signed a deal with the EC last November to supply up to 60 million doses of vaccine over two years, including 24.3 million doses in 2022.